Mechanism of Action

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the naturally occurring incretin hormone GLP-1. While the provided evidence includes several studies on semaglutide and GLP-1 receptor agonists, it contains limited detail about the specific molecular mechanisms of action.

Based on the available evidence, semaglutide works by activating GLP-1 receptors, which are found in various tissues including pancreatic beta cells, the gastrointestinal tract, and the brain. The evidence shows that GLP-1 receptor agonists like semaglutide are being studied across multiple therapeutic areas beyond diabetes, including weight management, alcohol reduction, methamphetamine use disorder, and idiopathic intracranial hypertension, suggesting broad physiological effects through GLP-1 receptor activation.

One study in the evidence examines "Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy," indicating that semaglutide influences appetite regulation and eating behavior, though the specific molecular pathways are not detailed in the provided abstracts.

Evidence Limitation: The provided research primarily focuses on clinical outcomes and real-world effectiveness rather than detailed mechanistic studies. For a complete understanding of semaglutide's molecular mechanism of action—including its effects on insulin secretion, glucagon suppression, gastric emptying, and central nervous system pathways—additional biochemical and pharmacological studies would be needed.

This information is for educational purposes only and should not replace professional medical advice. Consult your healthcare provider for personalized medical guidance.